Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 15 February, 2013 and appeared in  Children & TeensPractice MgmtNeuropathyIssue 664

Routine Screening for DPN in Children Needs to be Mandatory

Study calls for clinical guidelines for detecting DPN (diabetic peripheral neuropathy) in young patients….

Advertisement

The researchers reported that 26% of 151 children with Type 1 diabetes, aged 8 to 21 years, had a positive screening test for DPN.

This included six (75%) of eight patients at high-risk for DPN -- defined as age 13 years or older, diabetes duration of at least 5 years, and a HbA1c level of 10% or higher on two of the previous four measurements.

But 33 (23%) of the 143 patients who did not meet these risk criteria also had a positive screening test for DPN, which included a modified version of the Michigan Neuropathy Screening Inventory, a foot inspection, ankle reflex testing, monofilament (10 g) examination, and tuning fork testing. Follow-up with a pediatric neurologist confirmed DPN in five (62.5%) of the high-risk and 11 (46.0%) of the low-risk patients.

The average age of patients with confirmed DPN was 16.2 years. Although the average HbA1c was 8.7%, seven patients had a level equal to or below 8%. Average duration of diabetes in the DPN group was 6.4 years, but two patients had been diagnosed with diabetes within the past year.

Indeed, there was no significant correlation between diagnosis of DPN and patient age, duration of diabetes, HbA1c or cholesterol level, or height at puberty, although the researchers say this may be due to sample size or the cross-sectional study design.

This study highlights that DPN can occur in youth at any age and at any time from the onset of diagnosis.

Researchers added that, "These data raise our awareness of DPN in youth and challenge us to incorporate routine screening in practice as supported by research done outside of the US."

Diabetes Research and Clinical Practice, Feb 2013

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 15 February, 2013 and appeared in  Children & TeensPractice MgmtNeuropathyIssue 664

Past five issues: Diabetes Clinical Mastery Series Issue 208 | Issue 748 | GLP-1 Special Editions September 2014 | Diabetes Clinical Mastery Series Issue 207 | Issue 747 |

2014 Most Popular Articles:

Abbott Announces Approval of Its New Unique Continuous Glucose Monitor
Posted September 05, 2014
Low Carb Beats Low Fat
Posted September 05, 2014
FDA Approves Bupropion/Naltrexone (Contrave) for Obesity by Orexigen Therapeutics
Posted September 12, 2014
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus
Posted September 05, 2014
An Exclusive Interview with Al Mann, Founder and CEO, Mannkind Corp.
Posted September 15, 2014
Empagliflozin (Jardiance) SGLT-2 Inhibitor Now Available in Pharmacies
Posted August 29, 2014
Sleeve Gastrectomy Now a Common Choice for Bariatric Surgery
Posted September 12, 2014
Predicting Which Diabetics Will Develop Major Complications
Posted September 05, 2014
Type 2 Diabetes Diagnosis Needs to Be Changed: Prediabetes=Diabetes
Posted September 12, 2014
High-salt Diet and High HBA1c May Increase Cardiovascular Disease
Posted September 19, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Now that once-weekly dulaglutide has been approved, will you be prescribing it?
CME/CE of the Week
William Tamborlane, MD, FAAP, FACE

Category: General Diabetes
Credits:
 .75
Search Articles On Diabetes In Control